FMR1 and fragile X-associated tremor/ataxia syndrome: Future studies should aim to recruit individuals with genetically confirmed FXTAS in early disease stages or FMR1 premutation carriers who have not developed FXTAS who exhibit relatively preserved gait function at baseline and track them longitudinally to enable more meaningful interpretations of functional decline and clinically relevant disease progression.